Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
3.910
-0.100 (-2.49%)
At close: Jul 25, 2025, 4:00 PM
4.030
+0.120 (3.07%)
After-hours: Jul 25, 2025, 7:43 PM EDT
Skye Bioscience Employees
Skye Bioscience had 16 employees as of December 31, 2024. The number of employees increased by 5 or 45.45% compared to the previous year.
Employees
16
Change (1Y)
5
Growth (1Y)
45.45%
Revenue / Employee
n/a
Profits / Employee
-$2,040,682
Market Cap
121.15M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16 | 5 | 45.45% |
Dec 31, 2023 | 11 | 0 | - |
Dec 31, 2022 | 11 | 2 | 22.22% |
Dec 31, 2021 | 9 | 3 | 50.00% |
Dec 31, 2020 | 6 | 2 | 50.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
SKYE News
- 18 days ago - Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing - Seeking Alpha
- 4 weeks ago - Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 5 weeks ago - Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions - GlobeNewsWire
- 2 months ago - Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewsWire
- 2 months ago - Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab - GlobeNewsWire
- 2 months ago - Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity - GlobeNewsWire
- 2 months ago - Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript - Seeking Alpha